search
Back to results

HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial (HIP ATTACK-2)

Primary Purpose

Hip Fractures, Myocardial Injury

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Accelerated medical clearance and surgery
Sponsored by
Population Health Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hip Fractures

Eligibility Criteria

45 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. age ≥45 years;
  2. diagnosis of hip fracture during working hours with a low-energy mechanism requiring surgery;
  3. troponin elevation on hospital arrival (at least one troponin level from hip fracture occurrence to randomization above the upper limit of normal); and
  4. written informed consent.

Exclusion Criteria:

  1. taking a therapeutic dose of an anticoagulant for which no reversing agent is available;
  2. patients on a therapeutic vitamin K antagonist with a history of heparin induced thrombocytopenia (HIT);
  3. patients with peri-prosthetic fracture, open fracture or bilateral fractures;
  4. patients requiring an emergency surgery for another reason (e.g., subdural hematoma);
  5. patients with acute myocardial infarction with a mechanical complication (i.e., acute papillary muscle rupture, ventricular septal defect), ST elevation myocardial infarction, or cardiogenic shock;
  6. patients refusing consent; or
  7. patients previously enrolled in HIP ATTACK-2.

Sites / Locations

  • University of MarylandRecruiting
  • Lahey Hospital and Medical CenterRecruiting
  • University of MichiganRecruiting
  • Cleveland ClinicRecruiting
  • The John Hunter HospitalRecruiting
  • Cliniques Universitaires Saint Luc - University Catholic of LouvainRecruiting
  • University of Alberta HospitalRecruiting
  • St. Joseph's Healthcare HamiltonRecruiting
  • Juravinski HospitalRecruiting
  • Victoria HospitalRecruiting
  • Markham Stouffville HospitalRecruiting
  • Ottawa General HospitalRecruiting
  • South Karelia Central HospitalRecruiting
  • Tampere University HospitalRecruiting
  • Queen Mary HospitalRecruiting
  • IRCCS Ospedale Galeazzi- Sant'AmbrogioRecruiting
  • University of Malaya Medical CentreRecruiting
  • Cruz Verde GuadalajaraRecruiting
  • Christus Muguerza del ParqueRecruiting
  • B and B HospitalRecruiting
  • Deventer HospitalRecruiting
  • Shifa International Hospitals Ltd.Recruiting
  • Hayat Abad Medical ComplexRecruiting
  • Maroof International HospitalRecruiting
  • Ghurki Trust Teaching HospitalRecruiting
  • Combined Military HospitalRecruiting
  • SPZOZ MysleniceRecruiting
  • King Faisal Specialist HospitalRecruiting
  • Groote Schuur HospitalRecruiting
  • Stellenbosch University - Tygerberg HospitalRecruiting
  • Hospital Universitari Parc TauliRecruiting
  • Hospital Sant CamilRecruiting
  • Hospital Universitario Mutua de TerrassaRecruiting
  • Hospital Costa del SolRecruiting
  • Hospital Universitari Sagrat CorRecruiting
  • Hospital Universitari Vall d'HebronRecruiting
  • Hospital Clinic of BarcelonaRecruiting
  • Hospital de la Santa Creu I Sant PauRecruiting
  • Hospital Clinico Universitario de ValladRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Accelerated medical clearance and surgery

Standard surgical care

Arm Description

Accelerated medical clearance and targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.

Hip fracture repair and surgical care according to treating institution guidelines.

Outcomes

Primary Outcome Measures

All cause mortality
Death due to all causes

Secondary Outcome Measures

Ability to independently walk 3 meters
Ability to independently walk 3 meters (10 feet) or across a room without human assistance. Patients who require a cane or walker, but not human assistance, will be classified as able to walk independently. Patients who require assistance to get out of a chair, but can walk independently once they get up, will be classified as able to walk independently.
Composite of major complications
Composite includes vascular and nonvascular mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke.
Vascular mortality
Any death with a vascular cause and includes those deaths following a myocardial infarction, sudden cardiac arrest, stroke, cardiac revascularization procedure (i.e., percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery), heart failure, pulmonary embolus, cardiovascular hemorrhage, or deaths due to an unknown cause
Nonvascular mortality
Any death due to a clearly documented non-vascular cause.
Myocardial Infarction
Diagnosis of MI according to 4th universal definition of myocardial infarction
Acute Congestive Heart Failure
at least one clinical sign(s) or symptom(s) (e.g elevated jugular venous pressure, respiratory rales/crackles, crepitations, hypoxia, tachypnea or presence of S3) with at least one of the following: radiographic findings (i.e., vascular redistribution, interstitial pulmonary edema, or frank alveolar pulmonary edema) OR heart failure treatment implemented with diuretics with documented clinical improvement.
Stroke
Either - 1. a new focal neurological deficit thought to be vascular in origin with signs or symptoms lasting more than 24 hours or leading to death; or 2. a new focal neurological deficit thought to be vascular in origin with signs or symptoms lasting less 24 hours with a positive neuroimaging consistent with a stroke
Time from randomization to hospital discharge
Length of hospital stay from randomization to hospital discharge
Delirium
Patient meets the criteria for delirium on any in-person 3D-CAM administered; OR Positive history of delirium in the 7 days after randomization based on the review of hospital health records.
Moderate to severe pain
Moderate to severe pain is defined as any pain score ≥3 on 10 points scale.

Full Information

First Posted
February 3, 2021
Last Updated
July 4, 2023
Sponsor
Population Health Research Institute
Collaborators
Canadian Institutes of Health Research (CIHR)
search

1. Study Identification

Unique Protocol Identification Number
NCT04743765
Brief Title
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
Acronym
HIP ATTACK-2
Official Title
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 (HIP ATTACK-2) Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 22, 2021 (Actual)
Primary Completion Date
April 15, 2025 (Anticipated)
Study Completion Date
July 15, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Population Health Research Institute
Collaborators
Canadian Institutes of Health Research (CIHR)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. The trial will also assess secondary outcomes at 90 days after randomization: inability to independently walk 3 metres, time to first mobilization (first standing and first full weight bear), composite and individual assessment of major complications (e.g., mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke), delirium, length of stay, pain, and quality of life.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hip Fractures, Myocardial Injury

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
1100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Accelerated medical clearance and surgery
Arm Type
Experimental
Arm Description
Accelerated medical clearance and targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
Arm Title
Standard surgical care
Arm Type
No Intervention
Arm Description
Hip fracture repair and surgical care according to treating institution guidelines.
Intervention Type
Other
Intervention Name(s)
Accelerated medical clearance and surgery
Intervention Description
Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
Primary Outcome Measure Information:
Title
All cause mortality
Description
Death due to all causes
Time Frame
Within 90 days post randomization
Secondary Outcome Measure Information:
Title
Ability to independently walk 3 meters
Description
Ability to independently walk 3 meters (10 feet) or across a room without human assistance. Patients who require a cane or walker, but not human assistance, will be classified as able to walk independently. Patients who require assistance to get out of a chair, but can walk independently once they get up, will be classified as able to walk independently.
Time Frame
Within 90 days post randomization
Title
Composite of major complications
Description
Composite includes vascular and nonvascular mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke.
Time Frame
Within 90 days post randomization
Title
Vascular mortality
Description
Any death with a vascular cause and includes those deaths following a myocardial infarction, sudden cardiac arrest, stroke, cardiac revascularization procedure (i.e., percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery), heart failure, pulmonary embolus, cardiovascular hemorrhage, or deaths due to an unknown cause
Time Frame
Within 90 days post randomization
Title
Nonvascular mortality
Description
Any death due to a clearly documented non-vascular cause.
Time Frame
Within 90 days post randomization
Title
Myocardial Infarction
Description
Diagnosis of MI according to 4th universal definition of myocardial infarction
Time Frame
Within 90 days post randomization
Title
Acute Congestive Heart Failure
Description
at least one clinical sign(s) or symptom(s) (e.g elevated jugular venous pressure, respiratory rales/crackles, crepitations, hypoxia, tachypnea or presence of S3) with at least one of the following: radiographic findings (i.e., vascular redistribution, interstitial pulmonary edema, or frank alveolar pulmonary edema) OR heart failure treatment implemented with diuretics with documented clinical improvement.
Time Frame
Within 90 days post randomization
Title
Stroke
Description
Either - 1. a new focal neurological deficit thought to be vascular in origin with signs or symptoms lasting more than 24 hours or leading to death; or 2. a new focal neurological deficit thought to be vascular in origin with signs or symptoms lasting less 24 hours with a positive neuroimaging consistent with a stroke
Time Frame
Within 90 days post randomization
Title
Time from randomization to hospital discharge
Description
Length of hospital stay from randomization to hospital discharge
Time Frame
Within 90 days post randomization
Title
Delirium
Description
Patient meets the criteria for delirium on any in-person 3D-CAM administered; OR Positive history of delirium in the 7 days after randomization based on the review of hospital health records.
Time Frame
Within 7 days and 90 days post randomization
Title
Moderate to severe pain
Description
Moderate to severe pain is defined as any pain score ≥3 on 10 points scale.
Time Frame
Within 7 days and 90 days post randomization
Other Pre-specified Outcome Measures:
Title
New clinically important atrial fibrillation
Description
Documentation of atrial fibrillation or atrial flutter of any duration on an ECG or rhythm strip and results in angina, congestive heart failure, symptomatic hypotension, or requires treatment with a rate controlling drug, antiarrhythmic drug, or electrical cardioversion.
Time Frame
Within 90 days post randomization
Title
Cardiac revascularization procedure
Description
Revascularization procedures including coronary artery bypass graft or percutaneous coronary intervention surgery.
Time Frame
Within 90 days post randomization
Title
Venous thromboembolism
Description
Venous pulmonary embolism or deep venous thrombosis
Time Frame
Within 90 days post randomization
Title
Pulmonary embolism
Description
The diagnosis of PE requires any one of the following: A high probability ventilation/perfusion lung scan, An intraluminal filling defect of a segmental or larger artery on a helical CT scan, An intraluminal filling defect on pulmonary angiography, or A positive diagnostic test for DVT (e.g., positive compression ultrasound) and one of the following: A. Non-diagnostic (i.e., low or intermediate probability) ventilation/perfusion lung scan B. Non-diagnostic (i.e., subsegmental defects or technically inadequate study) helical CT scan.
Time Frame
Within 90 days post randomization
Title
Proximal deep venous thrombosis
Description
The diagnosis of proximal DVT requires: Thrombosis involving the popliteal vein or more proximal veins for leg DVT and axillary or more proximal veins for arm DVT, AND Evidence of vein thrombosis by any one of the following: 1. A persistent intraluminal filling defect on contrast venography, 2. Noncompressibility of one or more venous segments on B mode compression ultrasonography, or 3. A clearly defined intraluminal filling defect on contrast enhanced computed tomography.
Time Frame
Within 90 days post randomization
Title
Infection
Description
Pathologic process caused by the invasion of normally sterile tissue or fluid or body cavity by pathogenic or potentially pathogenic organisms.
Time Frame
Within 90 days post randomization
Title
Sepsis
Description
Based on the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) criteria,20 sepsis will require a quick Sequential Organ Failure Assessment (qSOFA) Score ≥2 points due to infection. The qSOFA includes the following items and scoring system: Altered mental status (1 point), Systolic blood pressure (SBP)of 100 mm Hg or less (1 point), and Respiratory rate (RR) of 22 breaths/min or more (1 point).
Time Frame
Within 90 days post randomization
Title
Pneumonia
Description
Acute infection of the pulmonary parenchyma that is associated with at least one sign or symptom of lower respiratory acute infection (e.g., cough, pleuritic chest pain) or acute systemic illness (e.g., fever, chills, confusion, hypoxemia); accompanied by the presence of an acute infiltrate/consolidation on a chest radiograph or auscultatory findings consistent with pneumonia (such as crackles and/or localized rales) for which there is no other explanation.
Time Frame
Within 90 days post randomization
Title
Bleeding
Description
Life threatening, major or critical organ bleeding
Time Frame
Within 90 days post randomization
Title
Hip reoperation
Description
Any second surgical procedure undertaken on the fractured hip being followed in the study, for any reason (e.g. infection, implant failure, periprosthetic fracture, wound dehiscence, etc.), after it has been initially repaired and the patient has left the operating room.
Time Frame
Within 90 days post randomization
Title
Prosthetic hip dislocation
Description
Any acute dislocation of a prosthetic femoral head from within its intended concentric location within the acetabulum. The acetabulum may or may not be resurfaced/replaced.
Time Frame
Within 90 days post randomization
Title
Implant failure
Description
Any mechanical issue related to the integrity of any component of the hip implant which requires a surgical procedure to correct. This includes: loss of implant fixation to bone (either with or without associated periprosthetic fracture); or broken, disassociated, or dislocated implant components.
Time Frame
Within 90 days post randomization
Title
Peri-prosthetic fracture
Description
Fracture through any part of either the femur and/or acetabulum to which a hip implant used for hip repair/reconstruction was fixed.
Time Frame
Within 90 days post randomization
Title
Acute kidney injury
Description
An increase in the serum creatinine concentration from the pre-randomization value of ≥26.5 μmol/L (≥0.3 mg/dL) within 48 hours after randomization, or an increase of ≥50% within 7 days after randomization.
Time Frame
Within 90 days post randomization
Title
Acute renal failure resulting in dialysis
Description
New requirement for dialysis (i.e., use of hemodialysis machine or peritoneal dialysis apparatus in patients without a requirement for dialysis prior to surgery).
Time Frame
Within 90 days post randomization
Title
Hospital re-admission
Description
Hospital re-admission following discharge from index hospitalization
Time Frame
Within 90 days post randomization
Title
Length of critical care stay
Description
Length of critical care stay
Time Frame
Within 90 days post randomization
Title
Length of rehabilitation stay
Description
Length of rehabilitation stay
Time Frame
Within 90 days post randomization
Title
Days alive at home
Description
Days alive at home are the number of days patients spend at their usual residence without, during that day, being admitted to a hospital or visiting an emergency department or urgent-care centre. Patients lose days alive at home if 1. patients go to an emergency department or urgent-care centre; 2. they become inpatients at a hospital or rehabilitation or convalescence-care facility; or 3. they die.
Time Frame
Within 90 days post randomization

10. Eligibility

Sex
All
Minimum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: age ≥45 years; diagnosis of hip fracture during working hours with a low-energy mechanism requiring surgery; troponin elevation on hospital arrival (at least one troponin level from hip fracture occurrence to randomization above the upper limit of normal); and written informed consent. Exclusion Criteria: taking a therapeutic dose of an anticoagulant for which no reversing agent is available; patients on a therapeutic vitamin K antagonist with a history of heparin induced thrombocytopenia (HIT); patients with peri-prosthetic fracture, open fracture or bilateral fractures; patients requiring an emergency surgery for another reason (e.g., subdural hematoma); patients with acute myocardial infarction with a mechanical complication (i.e., acute papillary muscle rupture, ventricular septal defect), ST elevation myocardial infarction, or cardiogenic shock; patients refusing consent; or patients previously enrolled in HIP ATTACK-2.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Valerie Harvey
Phone
905-297-3479
Ext
40793
Email
valerie.harvey@phri.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Flavia Borges, M.D
Organizational Affiliation
Population Health Research Institute
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Gerard Slobogean, M.D
Organizational Affiliation
University of Maryland, Baltimore
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Robert Feibel, M.D
Organizational Affiliation
The Ottawa Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
PJ Devereaux, M.D
Organizational Affiliation
Population Health Research Institute
Official's Role
Study Chair
Facility Information:
Facility Name
University of Maryland
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
20742
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Heather Phipps
Email
HPhipps@som.umaryland.edu
First Name & Middle Initial & Last Name & Degree
Gerard Slobogean, MD
Facility Name
Lahey Hospital and Medical Center
City
Burlington
State/Province
Massachusetts
ZIP/Postal Code
01805
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
John Garfi
Email
john.garfi@lahey.org
First Name & Middle Initial & Last Name & Degree
Andrew Marcantonio, MD
Facility Name
University of Michigan
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lyle Johnson
Email
lyjo@med.umich.edu
First Name & Middle Initial & Last Name & Degree
Jaimo Ahn, MD
Facility Name
Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laura Stiegel
Email
stiegel@ccf.org
First Name & Middle Initial & Last Name & Degree
Nicolas Piuzzi, MD
Facility Name
The John Hunter Hospital
City
New Lambton Heights
State/Province
New South Wales
ZIP/Postal Code
2305
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Debra McDougall
Email
Debra.McDougall@health.nsw.gov.au
First Name & Middle Initial & Last Name & Degree
Zsolt Balogh, MD
Facility Name
Cliniques Universitaires Saint Luc - University Catholic of Louvain
City
Woluwe-Saint-Lambert
State/Province
Brussels
ZIP/Postal Code
1200
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Simon Delande, MD
Email
simon.delande@saintluc.uclouvain.be
First Name & Middle Initial & Last Name & Degree
Patricia Lavand'homme, MD
Facility Name
University of Alberta Hospital
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 2B7
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maliha Muneer
Email
muneer@ualberta.ca
First Name & Middle Initial & Last Name & Degree
Mike Jacka, MD
Facility Name
St. Joseph's Healthcare Hamilton
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8N 4A6
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Abdul Rahman Muammar
Email
abdulrahm@HHSC.CA
First Name & Middle Initial & Last Name & Degree
Flavia Borges, MD
Facility Name
Juravinski Hospital
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8V 1C3
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Krysten Gregus
Email
gregus@HHSC.ca
First Name & Middle Initial & Last Name & Degree
Ameen Patel, MD
Facility Name
Victoria Hospital
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5W9
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Relka Bihari, MD
Email
Relka.Bihari@lhsc.on.ca
First Name & Middle Initial & Last Name & Degree
Reem Ansari
Email
Reem.Ansari@lhsc.on.ca
First Name & Middle Initial & Last Name & Degree
Abdel Lawendy, MD
Facility Name
Markham Stouffville Hospital
City
Markham
State/Province
Ontario
ZIP/Postal Code
L3P 7P3
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michelle Dimas
Email
mdimas@oakvalleyhealth.ca
First Name & Middle Initial & Last Name & Degree
Steve McMahon, MD
Facility Name
Ottawa General Hospital
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1H 8L6
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Katie Mcliquham
Email
kmcilquham@ohri.ca
First Name & Middle Initial & Last Name & Degree
Robert Feibel, MD
Facility Name
South Karelia Central Hospital
City
Lappeenranta
ZIP/Postal Code
53130
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lumikki Paananen
Email
lumikki.paananen@eksote.fi
First Name & Middle Initial & Last Name & Degree
Lauri Halonen, MD
Facility Name
Tampere University Hospital
City
Tampere
ZIP/Postal Code
33521
Country
Finland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Meri Järvinen, MD
Email
meri.jarvinen@pshp.fi
First Name & Middle Initial & Last Name & Degree
Aleksi Reito, MD
Facility Name
Queen Mary Hospital
City
Hong Kong
Country
Hong Kong
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Grace Ho
Email
gracehpy@hku.hk
First Name & Middle Initial & Last Name & Degree
Christian Fang, MD
Facility Name
IRCCS Ospedale Galeazzi- Sant'Ambrogio
City
Milan
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dario Pellegrino
Email
dar.pellegrini@gmail.com
First Name & Middle Initial & Last Name & Degree
Guiseppe De Blasio, MD
Facility Name
University of Malaya Medical Centre
City
Kuala Lumpur
ZIP/Postal Code
59100
Country
Malaysia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Khor Hui Min, MD
Email
Huimin81@yahoo.com
First Name & Middle Initial & Last Name & Degree
Chew Yin Wang, MD
Facility Name
Cruz Verde Guadalajara
City
Guadalajara
State/Province
Jalisco
ZIP/Postal Code
44410
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Claudia Ramirez, MD
Email
clauramirezg@me.com
First Name & Middle Initial & Last Name & Degree
Ricardo Madrigal, MD
Facility Name
Christus Muguerza del Parque
City
Chihuahua
ZIP/Postal Code
31000
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Avril Pérez
Email
avrilpf2108@gmail.com
First Name & Middle Initial & Last Name & Degree
Edmundo Berumen, MD
Facility Name
B and B Hospital
City
Lalitpur
State/Province
Bagmati
ZIP/Postal Code
44700
Country
Nepal
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Satish Prasad Barnawal, MD
Email
satishprasadbarnawal@gmail.com
First Name & Middle Initial & Last Name & Degree
Bibek Banskota, MD
Facility Name
Deventer Hospital
City
Deventer
State/Province
Overijssel
ZIP/Postal Code
7416 SE
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ellie Landman
Email
e.b.m.landman@dz.nl
First Name & Middle Initial & Last Name & Degree
Ydo Kleinlugtenbelt, MD
Facility Name
Shifa International Hospitals Ltd.
City
Islamabad
State/Province
ICT
ZIP/Postal Code
44000
Country
Pakistan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sumaira Gulzar
Email
sumairagulzar2050@gmail.com
First Name & Middle Initial & Last Name & Degree
Aamir Nabi Nur, MD
Facility Name
Hayat Abad Medical Complex
City
Peshawar
State/Province
KPK
ZIP/Postal Code
25000
Country
Pakistan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Muhammad Waqar, MD
Email
wkhan43@gmail.com
First Name & Middle Initial & Last Name & Degree
Muhammad Arif, MD
Facility Name
Maroof International Hospital
City
Islamabad
Country
Pakistan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Saboora Waris, MD
Email
saboora.waris@maroof.com.pk
First Name & Middle Initial & Last Name & Degree
Hassan Mumtaz
Email
hassan.mumtaz@maroof.com.pk
First Name & Middle Initial & Last Name & Degree
Mustafa Javed Bhalli, MD
Facility Name
Ghurki Trust Teaching Hospital
City
Lahore
Country
Pakistan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Omar Aziz, MD
Email
omaraziz40@hotmail.com
First Name & Middle Initial & Last Name & Degree
Khadeej Chaudry, MD
Email
Khadeej.ch@gmail.com
First Name & Middle Initial & Last Name & Degree
Amer Aziz, MD
Facility Name
Combined Military Hospital
City
Rawalpindi
Country
Pakistan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ahmed Mushtaq Khan, MD
Email
surgeon760@gmail.com
First Name & Middle Initial & Last Name & Degree
Muhammad Asif Rasheed, MD
Email
asifmalik256@hotmail.com
First Name & Middle Initial & Last Name & Degree
Muhammad Suhail Amin, MD
Facility Name
SPZOZ Myslenice
City
Myslenice
ZIP/Postal Code
32-400
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ilona Nowak-Kózka
Email
ilonnowak@gmail.com
First Name & Middle Initial & Last Name & Degree
Paweł Ślęczka, MD
Facility Name
King Faisal Specialist Hospital
City
Riyadh
ZIP/Postal Code
11211
Country
Saudi Arabia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Khawla Farhan, MD
Email
kalhydry@kfshrc.edu.sa
First Name & Middle Initial & Last Name & Degree
Husam Alrumaih, MD
Facility Name
Groote Schuur Hospital
City
Cape Town
State/Province
Western Cape
ZIP/Postal Code
7925
Country
South Africa
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Simphiwe Gumede
Email
simphiwe.gumede@uct.ac.za
First Name & Middle Initial & Last Name & Degree
Sithombo Maqungo, MD
First Name & Middle Initial & Last Name & Degree
Margot Flint, MD
Facility Name
Stellenbosch University - Tygerberg Hospital
City
Cape Town
Country
South Africa
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shanita Chhiba
Email
schhiba@sun.ac.za
First Name & Middle Initial & Last Name & Degree
Sean Chetty, MD
Facility Name
Hospital Universitari Parc Tauli
City
Sabadell
State/Province
Barcelona
ZIP/Postal Code
08208
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mireia Viñas
Email
mmvinas@tauli.cat
First Name & Middle Initial & Last Name & Degree
Jorge Serrano, MD
Facility Name
Hospital Sant Camil
City
Sant Pere De Ribes
State/Province
Barcelona
ZIP/Postal Code
08810
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alejandro Rodriguez Molinero
Email
arodriguez@csapg.cat
First Name & Middle Initial & Last Name & Degree
Alfred Dealbert, MD
Facility Name
Hospital Universitario Mutua de Terrassa
City
Terrassa
State/Province
Barcelona
ZIP/Postal Code
08221
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Judith Lopez
Email
jlopezcatena@mutuaterrassa.cat
First Name & Middle Initial & Last Name & Degree
Marti Bernaus, MD
Facility Name
Hospital Costa del Sol
City
Marbella
State/Province
Malaga
ZIP/Postal Code
29603
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alicia Ramirez-Roldan
Email
alicia_ram_rol@hotmail.com
First Name & Middle Initial & Last Name & Degree
Enrique Guerado, MD
Facility Name
Hospital Universitari Sagrat Cor
City
Barcelona
ZIP/Postal Code
08029
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maria del Mar Marti Ejarque
Email
mmmarti@quironsalud.es
First Name & Middle Initial & Last Name & Degree
Aamer Malik Khan, MD
First Name & Middle Initial & Last Name & Degree
Laura Ruiz-Villa, MD
Facility Name
Hospital Universitari Vall d'Hebron
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yaiza Garcia
Email
yaiza.garcia@vhir.org
First Name & Middle Initial & Last Name & Degree
Ernesto Guerra-Farfan, MD
Facility Name
Hospital Clinic of Barcelona
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Montsant Jornet Gibert, MD
Email
jornet@clinic.cat
First Name & Middle Initial & Last Name & Degree
Mariano Balaguer-Castro, MD
Facility Name
Hospital de la Santa Creu I Sant Pau
City
Barcelona
ZIP/Postal Code
08041
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ekaterine Popova Sherozia, MD
Email
EPopova@santpau.cat
First Name & Middle Initial & Last Name & Degree
Melixa Medina Aedo, MD
Email
melixa.ma@gmail.com
First Name & Middle Initial & Last Name & Degree
Jordi Martin Marcuello, MD
Facility Name
Hospital Clinico Universitario de Vallad
City
Valladolid
ZIP/Postal Code
47007
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Adela Pereda
Email
aperedama@gmail.com
First Name & Middle Initial & Last Name & Degree
Hector Aguado, MD

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
The Population Health Research Institute (PHRI) is the sponsor of this trial. The PHRI believes the dissemination of clinical research results is vital and sharing of data is important. PHRI prioritizes access to data analyses to researchers who have worked on the trial for a significant duration, have played substantial roles, and have participated in raising the funds to conduct the trial. PHRI balances the length of the research study, and the intellectual and financial investments that made it possible with the need to allow wider access to the data collected. Data will be disclosed only upon request and approval of the proposed use of the data by a Review Committee.

Learn more about this trial

HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial

We'll reach out to this number within 24 hrs